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Abstract
Purpose: Liquid biopsies, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), can be used
to understand disease prognosis, tumor heterogeneity, and dynamic response to treatment in metastatic breast
cancer (MBC). We explored a novel, 180-gene ctDNA panel and the association of this platform with CTCs and CTC
clusters.
Methods: A total of 40 samples from 22 patients with MBC were included in the study. For the primary analysis, all
patients had ctDNA sequencing using the PredicinePLUS™ platform. CTCs and CTC clusters were examined using
the CellSearch™ System. Clinical and pathological variables were reported using descriptive analyses. Associations
between CTC count and specific genomic alterations were tested using the Mann-Whitney U test.
Results: Of 43 sequenced patients, 40 (93%) had at least one detectable genomic alteration with a median of 6
(range 1–22). Fifty-seven different genes were altered, and the landscape of genomic alterations was representative
of MBC, including the commonly encountered alterations TP53, PTEN, PIK3CA, ATM, BRCA1, CCND1, ESR1, and MYC. In
patients with predominantly hormone-receptor-positive MBC, the number of CTCs was significantly associated with
alterations in ESR1 (P < 0.005), GATA3 (P < 0.05), CDH1 (P < 0.0005), and CCND1 (P < 0.05) (Mann-Whitney U test).
Thirty-six percent of patients had CTC clusters, which were associated with alterations in CDH1, CCND1, and BRCA1
(all P < 0.05, Mann-Whitney U test). In an independent validation cohort, CTC enumeration confirmed significant
associations with ESR1 and GATA3, while CTC clusters were significantly associated with CDH1.
Conclusions: We report on a novel ctDNA platform that detected genomic alterations in the vast majority of
tested patients, further indicating potential clinical utility for capturing disease heterogeneity and for disease
monitoring. Detection of CTCs and CTC clusters was associated with particular genomic profiles.
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Introduction
Liquid biopsies have emerged as clinical tools for prog-
nostication, molecular analysis, and detection of gen-
omic alterations in blood [1]. The most well-studied
components of liquid biopsies, circulating tumor cells
(CTCs) and circulating tumor DNA (ctDNA), give
insight into the “liquid phase” of solid tumors by provid-
ing information on the spatial and temporal heterogen-
eity of metastatic breast cancer (MBC). Applications
with potential clinical utility are being explored, includ-
ing detection of minimal residual disease, dynamic treat-
ment monitoring, and disease resistance [2, 3]. In MBC,
prior work demonstrated that CTC detection and enu-
meration defined two subgroups of patients, stage IVindo-
lent (< 5 CTCs per 7.5 mL of blood) and stage IVaggressive
(≥ 5 CTCs) [4, 5]. This staging has been previously vali-
dated to stratify patients into two predefined cohorts
with dramatically different prognostic outcomes, regard-
less of tumor type, site of disease, or line of therapy. Un-
derstanding the genomic changes that define these
cohorts of patients is critical.
In comparison to CTCs, CTC clusters, which consist
of aggregates of two or more cells, are encountered more
rarely in the circulation. However, these cell groupings
are associated with high metastatic potential, particular
DNA methylation patterns, and potentially poor progno-
sis [6–8]. Initial studies have explored the cellular and
genetic makeup of these cell groupings, but much re-
mains unknown regarding how these clusters form and
the genetic changes that contribute to the mechanisms
of how these groupings metastasize in breast cancer [9].
In MBC, ctDNA genomic alterations have been stud-
ied to understand the genetic heterogeneity of tumor re-
sistance. Specifically, markers of endocrine resistance
emerge in response to the selective pressures of endo-
crine therapy with either tamoxifen or aromatase inhibi-
tors as single agents or in combination with CDK4/6
inhibitors in MBC [10]. These events lead to clonal se-
lection and emergence of specific genomic alterations,
such as in RB1, PIK3CA driver mutations, and new ESR1
mutations. Furthermore, early changes in PIK3CA
ctDNA can predict progression-free survival for patients
treated with palbociclib and fulvestrant [11]. The impact
of novel sequencing ctDNA panels in terms of longer
DNA sequencing length and a greater number of gen-
omic alterations on detection of resistance mutations in
MBC is unknown.
Here, we explore the interplay between CTCs, CTC
clusters, and ctDNA genomic alterations in a cohort of
patients with predominantly hormone-receptor-positive
(HR+) MBC. For CTC detection and enumeration, we
utilized CellSearch™, and for ctDNA detection, we used
the PredicinePLUS™ 180-gene panel with independent
validation that was performed using Guardant360. These
studies explore the potential utility of these platforms
and how to integrate this information with other liquid-
biopsy-derived biomarkers. We demonstrate the analyt-
ical validity of this novel ctDNA platform and the associ-
ation of CTCs and CTC clusters with particular
mutational profiles.
Methods
Patient selection and study design
The Institutional Review Board (IRB) at the Robert H.
Lurie Comprehensive Cancer Center at the Northwest-
ern University Feinberg School of Medicine approved
the study. Informed consent from patients was waived
per the IRB. The study was performed in concordance
with the Health Insurance Portability and Accountability
Act. Forty-nine samples were initially evaluated. Six
samples had cfDNA yield less than 5 ng and, therefore,
did not pass quality control, based on having less than
90% of regions with greater than 3000X coverage. In
total, 40 of 43 (93%) passed next-generation sequencing
(NGS) quality control for sequencing. As a result, the
final cohort consisted of 40 samples from 22 patients
with MBC with all samples collected between 2016 and
2017. Sequencing was performed in two batches in
March and June 2018.
A cohort of patients with MBC with CTCs and CTC
clusters were identified for ctDNA sequencing. CTCs
were obtained under a prospective Investigator Initiated
Trial (IIT) (NU16B06) at the Robert H. Lurie Compre-
hensive Cancer Center at Northwestern University (Chi-
cago, IL, USA). CTC collection was performed at
baseline prior to initiation of the next line of treatment.
CTC detection and enumeration
CTC analysis was performed using the CellSearch™ Sys-
tem (Menarini Silicon Biosystems, PA, USA). Approxi-
mately 10 mL of whole blood was collected into CellSave
Stabilizing Tubes and processed via Celltracks Autoprep.
Immunomagnetic sorting was used to characterize epi-
thelial cell adhesion molecule (EpCAM)-positive, pan-
cytokeratin (CK)-positive, DAPI-positive, and CD45-
negative cells. Cells were reviewed via the Celltracks
Analyzer II. CTC clusters were characterized as an ag-
gregation of at least two cells with a distinct nuclei and
an intact cytoplasm membrane.
ctDNA sequencing
Patients with 10mL of whole blood specimens had
ctDNA sequencing from plasma performed using the
PredicinePLUS™ platform (Predicine, Inc., Hayward, CA,
USA). The platform includes a 180-gene panel with 565
kb of sequencing coverage including single nucleotide
variants (SNVs), copy number variants (CNVs), and a
total of 88 fusion genes (Additional file 1: Table S1).
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cfDNA yield was measured using Bioanalyzer 2100, and
sequencing was performed using an Illumina platform
with an in-house proprietary bioinformatics pipeline to
align ctDNA sequences and to determine genomic alter-
ations. Assay sensitivity was set at a minimum of 0.25%
mutant allele frequency (MAF) for all genomic regions
and 0.1% MAF for hotspot variants. Targeted sequencing
coverage was greater than 20,000X.
Based on a minimum cfDNA input of 15 nanograms
(ng), sensitivity for SNVs, CNVs, and gene fusions were
reported as 94.4%, 95.0%, and 83.3%, respectively, with
positive predictive values (PPV) of 99.7%, 100%, and
100%, respectively. Of note, NGS of these samples was
performed for research purposes only. Patients received
standard, guideline-based, systemic treatments. For inde-
pendent validation, NGS was performed on plasma sam-
ples in a subset of patients (N = 14) with concurrent
commercial Guardant360 testing (Guardant Health, Red-
wood City, CA) [12]. In addition, 84 patients with
Guardant360 testing and CTC evaluation were analyzed
to confirm associations between CTCs and particular
genomic alterations. CTC and ctDNA analyses were
linked to a deidentified clinical database.
Statistical analysis
Clinical and pathological variables were reported using
descriptive analyses. Associations between CTC count
and specific genomic alterations were tested using the
Mann-Whitney U test. All analyses were performed
using STATA (StataCorp (2015) Stata Statistical Soft-
ware: Release 14.2 College Station, TX: StataCorp, LP).
Results
Patient characteristics
Patient characteristics for the 22 MBC patients included
in the cohort are included in Table 1. All patients were
female. The sample consisted of 17 HR+, HER2-negative
patients, 1 HR-negative, HER2-positive, 1 HR+, HER2-
positive, and 3 triple-negative breast cancer patients.
There were 18 patients with invasive ductal carcinoma
(IDC) and 4 patients with invasive lobular carcinoma
(ILC). Median prior to lines of treatment in the meta-
static setting was 2 [range 0–7]. In total, 81.8% of pa-
tients had bone involvement and 68.2% had visceral
disease (Additional file 1: Table S2).
Platform characteristics
Forty samples from 22 patients were included in the
final analyses [range 1–4 samples per patient]. Of 43 ini-
tial samples, 40 passed NGS quality control (40/43, 93%)
and had detectable genomic alterations (Table 2). Mean,
median, and range for number of genomic alterations
were 6.7, 6.0, and 1–22, respectively. cfDNA yield ranged
Table 1 Patient characteristics
Cohort
Number of patients 22
Number of collections 40
Sex
Female 22 (100%)
Pathology
IDC 18 (81.8%)
ILC 4 (18.2%)
Histologic subtype
HR+, HER2− 17 (77.3%)
HR−, HER2+ 1 (4.5%)
HR+, HER2+ 1 (4.5%)
TNBC 3 (13.6%)
Clinical subtype
IBC 6 (27.3%)
Non-IBC 16 (72.7%)
Prior therapies in metastatic setting 2* [0–7]
Sites of disease
Bone 18 (81.8%)
Visceral 15 (68.2%)
CTC clusters
Yes 8 (36.4%)
No 14 (63.6%)
Total blood draws with clusters 14 (35.0%)
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, HR hormone
receptor, TNCB triple-negative breast cancer, IBC inflammatory breast cancer
*The median
Table 2 Characteristics of the PredicinePLUS™ platform and
detected alterations
Cohort
Total cases 49
Cases included in final analyses 40
Regions analyzed 180 genes
Panel size 565 kb
Samples with detectable alterations 40/43 (93%)
Number of genomic alterations
Mean 6.7
Median 6.0
Range 1–22
Number of genes with detected alterations 57
Variant allele frequency of detected
alterations
0.11–68.6%
Commonly detected SNV/indels TP53, PTEN, PIK3CA, ATM,
ESR1
Commonly detected copy number
amplifications
MYC, CCND1, PIK3CA
Commonly detected copy number losses BRCA1, CDKN2A, ATM
SNV single nucleotide variant, Indels insertion-deletion mutations
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from 7.8 to 272.5 ng. MAF of detectable mutations
ranged from 0.11 to 68.6%.
ctDNA genomic alterations
The landscape of genomic alterations in the cohort is in-
cluded in Fig. 1. Identified alterations were representa-
tive of commonly encountered tissue and blood-based
NGS alterations including the following: TP53, PTEN,
PIK3CA, ATM, BRCA1, CCND1, ESR1, and MYC. In
total, 267 genomic alterations from 57 different genes
were reported. Copy number gains were encountered in
16 genes and copy number losses in 5 genes. MAF of
common variants are shown in Additional file 1: Figure
S1. For patients with concurrent PredicinePLUS™ and
Guardant360 testing (N = 14), high concordance was ob-
served in orthogonal samples across representative gen-
omic alterations (ESR1 92.9%, PIK3CA 100%, MYC copy
number variations 71.4%) (Gerratana L, Zhang Z, Shah
A, Davis A, Zhan Y, Qiang W, Finkelman B, Flaum L,
Behdad A, Gradishar WJ et al: Analytical and clinical
performance of a novel next generation sequencing-
based (NGS) circulating tumor DNA (ctDNA) platform
for the evaluation of samples from metastatic breast can-
cer (MBC). In. Under Review; 2019).
Association of CTC enumeration with ctDNA alterations
Patients were categorized into stage IVindolent (< 5 CTCs
per 7.5 mL of blood) and stage IVaggressive (≥5 CTCs) dis-
ease based on CTC enumeration. In total, there were 8
patients (36%) with stage IVindolent and 14 patients (64%)
with stage IVaggressive at baseline CTC draw in the co-
hort. Samples with CDKN2A alterations had a signifi-
cantly lower number of CTCs (P < 0.05, Mann-Whitney
U test) (Fig. 2). In contrast, samples with a higher num-
ber of CTCs were significantly associated with alter-
ations in ESR1 (P < 0.005), GATA3 (P < 0.05), CDH1
(P < 0.0005), and CCND1 (P < 0.05) with stage IVaggressive
disease associated with ESR1 mutations (Mann-Whitney
U test). In independent validation using Guardant360
Fig. 1 Landscape of genomic alterations. Shown is a heatmap of all detected genomic alterations. Top blue panel indicates the total number of
alterations detected for each gene. The colors below indicate the specific types of genomic alterations including SNV/indels (red), copy number
gain (green), copy number loss (blue), and SNV/indel + copy number gain (yellow). Each row indicates a sample (N = 40) and each column
represents a gene
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testing of 84 patients, number of CTCs was confirmed
to have significant associations with ESR1 (P < 0.005)
and GATA3 (P < 0.05), as well as copy number changes
in MYC (P < 0.05). Characteristics of this cohort are in-
cluded in Additional file 1: Table S3.
Association of CTC clusters with ctDNA alterations
Eight patients (36%) were found to have CTC clusters in
at least one blood collection in the cohort. Furthermore,
12/40 (30%) of total blood draws contained CTC clus-
ters. All patients with CTC clusters had stage IVaggressive
Fig. 2 Genomic alterations associated with CTCs. Genomic alterations in ESR1, GATA3, CCND1, and CDH1 were significantly associated with higher
number of CTCs (P < 0.05, Mann-Whitney U test). In contrast, alterations in CDKN2A were more commonly observed in samples with low CTC
count (P < 0.05, Mann-Whitney U test). In the validation cohort, significant associations were confirmed for ESR1 (P < 0.005) and GATA3 (P < 0.05)
Fig. 3 Genomic alterations in patients with CTC clusters. Genomic alterations in CCND1, CDH1, and BRCA1 were significantly associated with the
number of CTC clusters (P < 0.05, Mann-Whitney U test). In the validation cohort, a significant association was confirmed for CDH1 (P < 0.005)
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disease. CTC clusters were significantly associated with
somatic genomic alterations in CDH1, CCND1, and
BRCA1 (all P < 0.05, Mann-Whitney U test) (Figs. 3 and
4). In the validation cohort, CTC clusters were signifi-
cantly associated with CDH1 (P < 0.005).
Case vignette
We present a case illustrating the potential clinical utility
for serial blood monitoring (Additional file 1: Figure S2).
The patient was a 67-year-old female with a history of
localized HR+ HER2-negative breast cancer treated with
lumpectomy and radiation who declined endocrine ther-
apy. About 2 years later, she developed right upper
quadrant pain and was found to have metastatic disease
to the liver, which was biopsy confirmed HR+ HER2-
negative breast adenocarcinoma. She was initiated on
single-agent anastrozole for approximately 2 years and
subsequently developed bone metastasis in her scapula
and lumbar spine. She was changed to fulvestrant (de-
clined palbociclib) and zoledronic acid with progression
of disease 4 months later in her liver and bones. At this
time, CTC evaluation demonstrated 45 CTCs of which 5
were HER2 positive with 2 CTC clusters present (time-
point 1). ctDNA NGS revealed an ERBB2 (HER2) S310F
mutation. Treatment was initiated with trastuzumab and
capecitabine. Serial CTC collection 3 months later re-
vealed 0 CTCs (timepoint 2). Eighteen months later,
after 22 cycles of trastuzumab, ctDNA revealed increas-
ing clonal heterogeneity with 9 alterations present in
blood including 5 different HER2 mutations and 9 CTCs
(1 HER2 positive) (timepoint 3). Subsequent imaging
confirmed progression of disease in the liver and lymph
nodes.
Discussion
The clinical potential for liquid biopsies, including CTCs
and ctDNA, for prognostication and disease monitoring
is expanding. We analyzed a novel, sensitive, 180-gene,
565-kb sequencing platform to analyze and report on
the landscape of alterations and association of genomic
changes with a cohort of predominantly HR+ MBC
characterized by CTC enumeration and CTC clusters.
The study demonstrated that using the sequencing
length of this platform, 100% of samples that passed
Fig. 4 Representative images of a patient with CTC clusters. Shown are representative images of a patient with CTC clusters with nuclear (DAPI)
and cytokeratin (CK-PE) staining. CD45 stains for non-CTC leukocytes. HER2/neu staining further distinguished CTCs from leukocytes in this
patient. This sample was associated with the following ctDNA genomic alterations: CDH1, TP53, NF1, PIK3CB, BRCA1, CCND1, CDK6, FGFR1, MET,
and MYC
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quality control and 40 of 43 that underwent sequencing
(93%) had at least one somatic alteration detected. This
suggests a clear potential for using this technique to de-
tect and monitor dynamic changes in the blood of pa-
tients with MBC. In total, 57 genes with genomic
alterations were detected including SNVs, indels, and
CNVs. Longer sequencing panels may also aid in identi-
fying novel resistance mutations in blood and better
represent tumor heterogeneity to eventually capture
tumor mutational burden, non-invasively.
We observed that higher number of CTCs was associ-
ated with genomic alterations in ESR1, GATA3, CDH1,
and CCND1, while lower number of CTCs was associ-
ated with CDKN2A alterations. In independent valid-
ation, these findings were confirmed for ESR1 and
GATA3. This supports the relation between CTCs as a
marker of poor prognosis and the ability to detect spe-
cific resistance mutations (e.g., ESR1) with implications
for clinical practice. Prior work in our group has demon-
strated that ESR1 mutations in single CTCs matched
mutations observed in ctDNA, which demonstrates a
mechanism to link CTCs with the release of ctDNA into
the blood [13]. Furthermore, alterations in CDH1,
CCND1, and BRCA1 were associated with a higher num-
ber of CTC clusters with the validation cohort confirm-
ing CDH1 as statistically significant. The CDH1 gene is
involved in the production of epithelial cadherin (E-cad-
herin). Therefore, the gene plays a role in cell adhesion,
chemical signaling, and cell movement, all of which may
contribute to the metastatic process. Somatic variants in
CDH1 were seen in both ILC and IDC patients in our
cohort, although classically this mutation is associated
with ILC histology [14]. Further studies are needed to
explore this mutation as an indicator of metastatic
potential.
Conclusions
In summary, this novel ctDNA sequencing platform
identified genomic alterations in the vast majority of
tested patients, reflecting the genomic heterogeneity of
patients with predominantly HR+ MBC. This suggests a
clear clinical potential for disease monitoring using this
platform given the frequency of genomic alterations en-
countered in our sample. Additional analyses enabled us
to characterize particular genomic alterations and differ-
ent biology based on CTC enumeration and the identifi-
cation of CTC clusters. Limitations of this study include
the relatively small sample size and that some patients
with more than one ctDNA sample could have biased
the analyses of specific ctDNA alterations. However,
these data are consistent with previous experiences using
different NGS platforms and were validated in an inde-
pendent cohort in our study [15]. These findings,
therefore, further demonstrate the potential of combin-
ing CTCs and ctDNA for comprehensive liquid biopsy
analysis to accurately represent genomic heterogeneity
and to detect resistance mutations in a non-invasive
manner with implications for clinical management of pa-
tients with MBC.
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